Charles River Laboratories and FibroBiologics Sign Letter of Intent for Drug Manufacturing

• FibroBiologics Inc. and Charles River Laboratories have signed a letter of intent for technology transfer and collaboration.

• Charles River will conduct feasibility studies on FibroBiologics’ cell manufacturing processes and potentially serve as the CDMO for their clinical trials.

FibroBiologics Inc. and Charles River Laboratories have announced a significant step in their collaboration, signing a letter of intent that paves the way for enhanced drug development and manufacturing capabilities.

FibroBiologics Inc., a clinical-stage biotechnology company specializing in therapies using fibroblasts, and Charles River Laboratories, a global leader in drug discovery and development solutions. The agreement includes technology transfer, testing, and validation of FibroBiologics’ innovative technology, with a focus on developing therapies for chronic diseases. The letter of intent has been signed, with plans to enter into a master services agreement for further collaboration.

The collaboration will involve Charles River conducting feasibility studies on FibroBiologics’ cell manufacturing processes within its facilities. FibroBiologics aims to advance its fibroblast-based therapies into clinical trials, leveraging Charles River’s expertise in cell and gene therapy development and manufacturing. If the master services agreement is finalised, Charles River will serve as the contract development and manufacturing organization (CDMO) responsible for producing drug products for FibroBiologics’ clinical trials.

Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics commented, “We are proud to discuss opportunities to work with Charles River, a global leader in cell and gene therapy development and manufacturing, as we look to advance our unique fibroblast-based spheroids into the clinic. We are both committed to bringing innovative and potentially curative therapies to patients suffering from chronic diseases.”